Objective: To examine the extent to which circulating levels of omentin and fractalkine are dependent on the degree of adipose tissue accumulation, waist circumference, plasma insulin and НО??-IR in representatives of Ukrainian population.

Materials and Methods: 250 individuals mean age of 65.48±11.86 years were examined; waist circumference was measured; adipose tissue mass was assessed by bio-impedance with relative body weight. Content of insulin, blood fractalkine and omentin were determined by immune enzyme method and НО??-IR index was calculated.

Results: There was an inverse correlation between blood fractalkine and omentin levels(r = -0.863, p<0.001). Blood fractalkine level correlates positively with adipose mass of the body(r=0.5341, p<0.001)); waist circumference- (r =0.4542, p<0.001); insulinemia (r =0.7798, p<0.001) and НО??-IR levels (r= 0.745, p<0.001). Omentin level correlates negatively with adipose body mass(r = -0.609, p<0.001); waist circumference- (r = -0.397, p<0.001); insulinemia (r = -0.799, p<0.001) and НО??-IR levels (r = -0.7706, p<0.001). The data also showed that accumulation of adipose mass greater than 25% of total body mass determines an increase in blood fractalkine levels up to750 ng/mL and higher, and НО??-IR> 2.77 is associated with decreased omentin levels down to500 ng/mL and less.

Conclusion: These data indicate strong associations, which suggest that there may be an important role for fractalkine and omentin in markers of diabetes mellitus and obesity.


O. Lavrynenko: None. N. Kravchun: None. K. Misura: None. O. Zemlianitsyna: None. I. Dunaeva: None. P. Kravchun: None. R.A. DeFronzo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Elcelyx Therapeutics, Inc., Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc. Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc. Speaker's Bureau; Self; AstraZeneca, Novo Nordisk Inc. E. Cersosimo: None. I. Karachentsev: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.